Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance Dual therapy : - with metformin : Moderate
Tritherapy : - with metformin and a sulfonylurea : Moderate - with insulin and metformin : Moderate
|
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance - with insulin : Insufficient for reimbursement by National Health Insurance
|
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin : In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable.
|
| Not applicable |
|
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
CRpCK0FFWwUFqKVN